文献速递产科母胎医学

凝血酶生成试验动力学扰动识别妊娠早期有子痫前期风险的女性并为预防策略提供依据

Perturbations in kinetics of the thrombin generation assay identify women at risk of preeclampsia in the first trimester and provide the rationale for a preventive approach.
PubMed 文献 · Am J Obstet Gynecol · 2022-11-08

该回顾性巢式病例对照研究基于前瞻性纵向单胎妊娠队列,比较正常妊娠(n=45)与子痫前期(n=49,早发24例、晚发25例)孕妇妊娠期凝血酶生成试验参数变化。子痫前期患者早在妊娠8至16周即出现异常凝血酶生成动力学;短滞后时间联合高峰凝血酶浓度在8至16周的比值比为43.87(曲线下面积0.79,灵敏度56.8%,特异度92.7%,阳性似然比7.76)。结论认为凝血酶生成试验可在妊娠早期识别子痫前期高危亚组,为在该亚组中测试低分子肝素疗效提供依据。

要点

  • 子痫前期患者早在妊娠8至16周即出现凝血酶生成动力学异常。
  • 8至16周短滞后时间联合高峰凝血酶浓度的比值比为43.87。
  • 16至22周短滞后时间联合高速度指数的比值比为16。

核心结论

  • 妊娠早期凝血酶生成试验可识别因凝血酶生成加速和增强而子痫前期风险较高的患者亚组。
  • 该观察结果为在该亚组中测试低分子肝素疗效提供了依据。
  • 作者提出未来关于低分子肝素及其他靶向凝血系统干预预防子痫前期 efficacy 的研究应聚焦于凝血酶生成动力学异常的患者。

研究设计与样本

  • 回顾性巢式病例对照研究,基于前瞻性纵向单胎妊娠队列。
  • 病例为发生子痫前期的女性(n=49),对照为正常妊娠患者(n=45)。
  • 子痫前期分为早发(n=24)和晚发(n=25)。
  • 比较各组妊娠期凝血酶生成试验参数(滞后时间、达峰凝血酶浓度时间、高峰凝血酶浓度、内源性凝血酶生成、速度指数)的纵向变化,并从对照组推导正常妊娠百分位数。
  • 时间相关参数<第10百分位视为短,浓度相关参数>第90百分位视为高。

主要发现

  • 发生子痫前期(早发和晚发)的患者早在妊娠8至16周即出现异常凝血酶生成动力学。
  • 妊娠8至16周短滞后时间联合高峰凝血酶浓度者后续发生子痫前期的比值比为43.87(曲线下面积0.79,灵敏度56.8%,特异度92.7%,阳性似然比7.76)。
  • 妊娠16至22周短滞后时间联合高速度指数者后续发生子痫前期的比值比为16(曲线下面积0.78,灵敏度62.2%,特异度92.5%,阳性似然比8.29)。

关键数值与推荐

  • 时间相关参数<第10百分位视为短。
  • 浓度相关参数>第90百分位视为高。
  • 8至16周短滞后时间联合高峰凝血酶浓度:比值比43.87,曲线下面积0.79,灵敏度56.8%,特异度92.7%,阳性似然比7.76。
  • 16至22周短滞后时间联合高速度指数:比值比16,曲线下面积0.78,灵敏度62.2%,特异度92.5%,阳性似然比8.29。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Activation of the coagulation system and increased thrombin generation have been implicated in the pathophysiology of preeclampsia, and this rationale supports the administration of low-molecular-weight heparin to prevent this syndrome in patients at risk. Yet, randomized trials of this prophylactic measure have yielded contradictory results. A possible explanation is that only a subset of patients with preeclampsia have excessive thrombin generation and would benefit from the administration of low-molecular-weight heparin. Therefore, the key questions are whether and when patients who subsequently develop preeclampsia present evidence of abnormal thrombin generation. OBJECTIVE: This study aimed to determine (1) the kinetics of thrombin generation throughout gestation in women with a normal pregnancy and in those with early and late preeclampsia, and (2) the diagnostic performance of in vivo thrombin generation parameters to predict the development of preeclampsia. STUDY DESIGN: This retrospective, nested case-control study was based on a prospective longitudinal cohort of singleton gestations. Cases comprised women who developed preeclampsia (n=49), and controls consisted of patients with a normal pregnancy (n=45). Preeclampsia was classified into early-onset (n=24) and late-onset (n=25). Longitudinal changes in the parameters of the thrombin generation assay (lag time, time to peak thrombin concentration, peak thrombin concentration, endogenous thrombin generation, and velocity index) throughout gestation were compared between the study groups, and normal pregnancy percentiles were derived from the control group. We tested whether a single parameter or a combination of parameters, derived from the kinetics of thrombin generation, could identify patients who subsequently developed preeclampsia. Time-related parameters <10th percentile were considered short, and concentration-related parameters >90th percentile were considered high. RESULTS: (1) Patients who developed preeclampsia (early- and late-onset) had abnormal thrombin generation kinetics as early as 8 to 16 weeks of pregnancy; (2) patients with a combination of a short lag time and high peak thrombin concentration at 8 to 16 weeks of pregnancy had an odds ratio of 43.87 for the subsequent development of preeclampsia (area under the curve, 0.79; sensitivity, 56.8%; specificity, 92.7%; positive likelihood ratio, 7.76); (3) at 16 to 22 weeks of gestation, patients with a combination of a short lag time and a high velocity index had an odds ratio of 16 for the subsequent development of preeclampsia (area under the curve, 0.78; sensitivity, 62.2%; specificity, 92.5%; positive likelihood ratio, 8.29). CONCLUSION: During early pregnancy, the thrombin generation assay can identify the subset of patients at a greater risk for the development of preeclampsia owing to accelerated and enhanced production of thrombin. This observation provides a rationale for testing the efficacy of low-molecular-weight heparin in this subset of patients. We propose that future research on the efficacy of low-molecular-weight heparin and other interventions targeting the coagulation system to prevent preeclampsia should be focused on patients with abnormal kinetics of thrombin generation.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Erez O, Gotsch F, Jung E, et al. Perturbations in kinetics of the thrombin generation assay identify women at risk of preeclampsia in the first trimester and provide the rationale for a preventive approach. Am J Obstet Gynecol. 2022. PMID: 36368431. doi:10.1016/j.ajog.2022.11.1276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。